Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Active, not recruiting Not applicable

An Evaluation of the WHO QUAlityRights Program

NCT06874439 · tracked via the Priya Life Science France tracker
Sponsor
GCS-CCOMS
Phase
Not applicable
Started
2024-06-17
Last updated
2026-10-15

Condition(s) studied

RecoveryOrganization of Health ServiceMental Health CareMental Health Services

Investigational drug(s) / intervention(s)

WHO QualityRights program

WHO QualityRights program: The WHO's QualityRights program involves an assessment, called observation, of mental health care services by an ephemeral multidisciplinary team, which provides feedback and recommendations for improving care practices. The observation team, trained in the QualityRights (QR) methodology, includes mental health professionals, researchers, legal experts, and management staff from mental health organizations. Each team always incorporates at least one expert by experience and one informal caregiver or family member. Participation in the program is voluntary and initiated at the request of healthcare facilities. The observation is structured into three stages: 1. Site preparation 2. On-site observation 3. Restitution of observation report and follow-up

Study summary

The World Health Organization's (WHO) QualityRights (QR) program offers assessments and recommendations to help mental health facilities, on a voluntary basis, improve their care practices towards better respect of the rights of service users. The aim of this study is to evaluate the QR program in a French national context.

The main questions it aims to answer are:

* Does the QR program improve perceived satisfaction with care among mental health service users?
* What are the implementation procedures of the program?
* What is its budgetary impact?

Researchers will compare the QR program intervention with usual practices.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Adults (18 years or older) * Persons having formulated a non-opposition to participate in the study * Population a (users): Service users of the psychiatric sectors involved in the study hospitalized full-time since at least 3 days in an inpatient unit. * Population b (professionals): Mental health professionals working in the sector since at least 3 months at the time of study participation Exclusion Criteria: * Persons physically or psychologically unable to participate at the time of the study * Persons subject to a safeguard of justice measure * Persons who do not speak or understand the French language

Primary outcome measure(s)

  • Satisfaction with care — At baseline, at 1 year, and at 2 years
    Service user satisfaction with care score assessed using the Verona Service Satisfaction Scale (VSSS-EU)

Trial sites (10)

FacilityCityRegionStatus
Public mental health establishment of Lille Metropole (59G09/G10) Armentières France
Public mental health establishment of Lille Metropole (59G20) Armentières France
Hospital Centre of Erstein Erstein France
Psychotherapeutic Center of Nancy Laxou France
Hospital Centre Drôme Vivarais Montéléger France
Hospital Care Center of Nanterre Nanterre France
Hospital Centre Sainte-Marie Nice Nice France
Hospital Center of Plaisir (78G16) Plaisir France
Hospital Center of Plaisir (78G18) Plaisir France
Hospital Center of Candélie Pont-du-Casse France

More GCS-CCOMS trials in France

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06874439 on ClinicalTrials.gov ↗ ← All trials in France